Vimarsana
Biggest News Aggregation in the World

Meru Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Meru Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Meru Phase Today - Breaking & Trending Today

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and ... - Vimarsana News

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and ... Merus N.V.January 12, 2021 GMT UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and...

Source: apnews.com
Investegate |Merus N.V. Announcements | Merus N.V.: Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of Zenocutuzumab - Vimarsana News

Investegate |Merus N.V. Announcements | Merus N.V.: Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of Zenocutuzumab

Forward-Looking Statements  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, Sema4’s performance under the agreement to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring NRG1 gene fusions, who may be eligible for investigational treatment with Zeno in the eNRGy trial; the companies’ plan to sup...